ストックスクリーナーアプリを入手
175.58
2.37%
4.06
前日終値:
$171.52
開ける：
$171.794
24時間の取引高:
12.92M
Relative Volume:
2.28
時価総額：
$310.27B
収益：
$55.53B
当期純損益:
$5.12B
株価収益率:
48.10
EPS:
3.65
ネットキャッシュフロー:
$15.62B
1週間 パフォーマンス:
+1.27%
1か月 パフォーマンス:
+4.66%
6か月 パフォーマンス:
+2.00%
1年 パフォーマンス:
+15.75%
1日の値動き範囲:
$170.66
$176.80
1週間の範囲:
$170.21
$176.80
52週間の値動き範囲:
$151.29
$207.32
Abbvie Inc Stock (ABBV) Company Profile
ABBV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-04 | アップグレード | Argus | Hold → Buy |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-06-05 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-01-29 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-12-11 | アップグレード | Goldman | Neutral → Buy |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-30 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-07-25 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-05 | ダウングレード | Argus | Buy → Hold |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-22 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-11-08 | ダウングレード | Societe Generale | Buy → Hold |
| 2022-08-01 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Underperform |
| 2022-05-06 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-02-28 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-03 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-03 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-03 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-03 | 繰り返されました | Goldman | Neutral |
| 2022-01-13 | 開始されました | Redburn | Buy |
| 2022-01-12 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-11-23 | アップグレード | Societe Generale | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-23 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | アップグレード | Argus | Hold → Buy |
| 2020-05-18 | 再開されました | BofA/Merrill | Neutral |
| 2020-05-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 再開されました | Morgan Stanley | Overweight |
| 2020-04-20 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 繰り返されました | Cowen | Outperform |
| 2019-09-26 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-20 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-04-29 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
すべてを表示
Abbvie Inc (ABBV) 最新ニュース
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally - The Motley Fool
Abbvie - Contract Pharma
AbbVie (NYSE:ABBV) Stock Price Up 2%Here's What Happened - MarketBeat
AbbVie, Novartis and drug industry win court battle in larger 340B war - Crain's Chicago Business
Alembic Pharma Gains USFDA Approval for Epilepsy Treatment - Devdiscourse
GLP-1 Receptor Agonist Market Is Booming Worldwide 2024-2031:Verrica Pharmaceuticals,AbbVie Inc,Glenmark - EIN News
AbbVie Inc. stock underperforms Thursday when compared to competitors - MarketWatch
AI & Data Convergence - AbbVie
AbbVie (NYSE:ABBV) Trading Down 0.5% After Insider Selling - MarketBeat
AbbVie acquiring Madison-based Nimble Therapeutics for $200 million - Milwaukee Journal Sentinel
AbbVie's atogepant and onabotulinumtoxinA receive strong recommendations in the newly updated Canadian Headache Society (CHS) Migraine Prevention Guideline - Kilgore News Herald
Is AbbVie Inc. (ABBV) the Safest Dividend Stock to Invest In Now? - Insider Monkey
Acellular Dermal Matrices Market Projected To Witness Substantial Growth, 2024-2031: Stryker Corporation, - EIN News
Abbvie SVP Kevin Buckbee sells stock for $310,032 - Investing.com India
Kevin K. Buckbee Sells 1,800 Shares of AbbVie Inc. (NYSE:ABBV) Stock - MarketBeat
ASH: AbbVie/Genmab Look To Stake Anti-CD20 Bispecific Claim In CLL - Citeline News & Insights
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novartis, AbbVie Score Win to Block West Virginia Drug Limit Law - Bloomberg Law
AbbVie's SWOT analysis: biopharma giant navigates post-Humira landscape - Investing.com
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance
AbbVie Inc. (NYSE:ABBV) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Biologics Market to See Booming Growth 2024-2031 | AbbVie Inc., - openPR
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie's (ABBV) Overweight Rating Reiterated at Piper Sandler Companies - MarketBeat
Bain Sued Over Cerevel Trades Before $8.7 Billion Sale to AbbVie - Bloomberg Law
AbbVie (NYSE:ABBV) Price Target Raised to $220.00 at Piper Sandler - MarketBeat
4 Big Drug Stocks That May Continue to Outperform in 2025 - Yahoo Finance
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back? - Yahoo! Voices
Spinal Cord Injury Therapeutics Market Set to Witness Significant Growth by 2024-2031: AbbVie Inc, Pfizer - EIN News
Immunology Market Huge Growth in Future Scope 2024-2031 | AbbVie - openPR
Is AbbVie Ready for a Bullish Turn? - Investing.com
Botulinum Toxin in Urology Market Top PlayersAbbVie Inc., Merz Pharma; Ipsen Pharma; GALDERMA; Allergan PLC. - openPR
AbbVie Stock Volatile On $200M Deal To Buy Nimble Therapeutics: Retail Still Bearish - MSN
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Why Investors Should Watch AbbVie Inc (ABBV) - See It Market
AbbVie: Pullback Is A Golden Opportunity For Dividend And Growth Investors - Seeking Alpha
AbbVie (ABBV) Acquires Nimble Therapeutics for $200 Million - GuruFocus.com
AbbVie Enters Oversold Territory - Forbes
AbbVie, Novartis Drop Suit Over Kansas Drug Discount Limit Law - Bloomberg Law
ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock? - Yahoo Finance
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline - Yahoo Finance
AbbVie continues deal-making spree with $200M Nimble buy - PharmaLive
AbbVie Continues Deal-Making Spree With $200M Nimble Buy - BioSpace
AbbVie adds psoriasis med with Nimble takeover - pharmaphorum
AbbVie to acquire Nimble Therapeutics for $200m - Yahoo Finance
Alzheimers Drugs Market to See Booming Growth 2024-2031 | - openPR
AbbVie to acquire Nimble Therapeutics in $200m deal - World Pharmaceutical Frontiers
AbbVie Parkinson’s Drug Rejected by FDA After Plant Inspection - MSN
AbbVie Inc. (NYSE:ABBV) Stock Position Lowered by Lord Abbett & CO. LLC - MarketBeat
B. Riley Wealth Advisors Inc. Decreases Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie (ABBV) Announces Leadership Transition in Financial Department - GuruFocus.com
Abbvie Inc (ABBV) 財務データ
収益
当期純利益
現金流量
EPS
0.62%
1.48%
大文字化:
|
ボリューム (24 時間):